Dr. Dana Kent Hays, D.O. Emergency Medicine - Emergency Medical Services Medicare: Not Enrolled in Medicare Practice Location: 1248 Macdowell St, Alturas, CA 96101 Phone: 530-233-5131 |
News Archive
On Dec. 21, the U.S. Food and Drug Administration approved Juxtapid (lomitapide) to reduce low-density lipoprotein (LDL) cholesterol, total cholesterol, apolipoprotein B, and non-high-density lipoprotein (non-HDL) cholesterol in patients with homozygous familial hypercholesterolemia (HoFH). Juxtapid is intended for use in combination with a low fat diet and other lipid-lowering treatments.
The key to control any pandemic is early identification and rapid response.
Patterson Companies, Inc. today reported consolidated sales of $789,579,000 for the first quarter of fiscal 2010 ended July 25, an increase of 6% from $743,859,000 in the year-earlier quarter. The strong performance of technology offerings in the dental equipment business, as well as higher sales of veterinary supplies, helped offset the impact of the weak economy on other portions of Patterson's business. Acquisitions, net of negative foreign currency adjustments, accounted for the majority of the first quarter sales growth. Net income was $45,057,000 or $0.38 per diluted share, compared to $45,964,000 or $0.39 per diluted share in the first quarter of 2009.
Ultrasound will be able to depict blood flow with more detail and accuracy using Toshiba America Medical Systems, Inc.'s new innovative ultrasound technology (works-in-progress).
Impulse Monitoring, Inc. (IMI), a leading provider of intraoperative neurophysiological monitoring (IONM) services to hospitals, today announced that it has signed an agreement with the University of California-Irvine Medical Center to provide supplemental IONM technologist and real-time physician oversight support services.
› Verified 9 days ago